Dose-related Effect of Aspirin on Laboratory-defined Acetylsalicylic Acid Resistance and Clinical Outcome After Coronary Stenting

Shiraz University of Medical Sciences106 enrolled

Overview

The investigators prospectively studied the effect of aspirin on platelet function in 106 stable outpatients 6 months after successful percutaneous coronary angioplasty. Participants were randomized in a double-blind, double-crossover study (80 or 500 mg per day for 6 months).T

Background: Acetylsalicylic acid (aspirin) is widely used in the secondary prevention of coronary artery disease. There is controversy regarding the prevalence of aspirin resistance in patients with coronary artery disease and the effect of dose on resistance. Our primary aims were to determine the degree of platelet responsiveness to aspirin, and to study the influence of dose on platelet inhibition and clinical outcomes after coronary stenting.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

106

Conditions

Coronary Stenting

Interventions

80 mg ASA dosingDRUG

500 mg ASA dosingDRUG

Eligibility

Sex: ALLMin age: 40 YearsMax age: 67 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 6 months post stent without complication Exclusion Criteria: * subacute stent thrombosis * unable to discontinue plavix * dont accept to participate * contraindication for ASA use

Locations (1)

Namazi hospital

Shiraz, Fars, Iran

Outcomes

Primary Outcomes

laboratory ASA resistance

Time frame: 6 months

Secondary Outcomes

major adverse cardiac events and positive cardiac scan for ischemia

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.